Increased risk of symptomatic gallbladder disease in adults with Down syndrome
Fairview/Cleveland Clinic Family Practice Residency, 18200 Lorain Avenue, Cleveland, OH 44111, USA.American Journal of Medical Genetics Part A (Impact Factor: 2.16). 11/2004; 130A(4):351-3. DOI: 10.1002/ajmg.a.30243
Previous reports have documented an increased prevalence of asymptomatic cholelithiasis among children with Down syndrome. Whether this predisposes adults with Down syndrome to symptomatic gallbladder disease has not been studied. A case control study compared the rate of symptomatic gallbladder disease in 28 index cases of adults with Down syndrome and that of sex-matched controls. The rate of gallbladder disease was 25% among the Down syndrome group, compared to 4.5% among the control group (P = 0.002). Patients with Down syndrome were also more likely to have a family medical history of gallbladder disease. Utilizing logistic regression analysis, the adjusted relative risk for gallbladder disease among individuals with Down syndrome was 3.52.
- Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi 09/2004; 45(5):264.
- [Show abstract] [Hide abstract]
ABSTRACT: Individuals with Down syndrome (DS) have a predisposition to leukaemia and testicular cancer, but data on the incidence of cancers are yet sparse. A cohort of 3,581 persons with DS was identified from a National Registry of Finnish persons with intellectual disability collected between 1978 and 1986 and followed-up for cancer incidence until 2002. Standardised incidence ratios (SIRs) were defined as ratios of observed number of cancer cases to those expected from the national cancer incidence rates, by age and sex. The overall cancer risk was equal to that of the general population, but a significantly high risk of leukaemia (SIR 10.5, CI 95% 6.6-15.8) and testicular cancer (SIR4.8, CI 95% 1.8-10.4) was found.International Journal of Cancer 04/2006; 118(7):1769-72. DOI:10.1002/ijc.21518 · 5.09 Impact Factor
- Diseases of the Gallbladder and Bile Ducts: Diagnosis and Treatment, Second Edition, 10/2007: pages 216 - 228; , ISBN: 9780470986981
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.